Ospedale Ruber Internacional
| Turchia | Austria | Spagna | |
| Radioterapia per il cancro colorettale | da $7,000 | da $12,000 | da $10,000 |
| Chemioterapia per carcinoma mammario | da $1,200 | da $15,000 | da $3,500 |
Il medico ha una vasta esperienza nel campo dell'oncologia peritoneale, attualmente lavora presso il Dipartimento di Carcinomatosi Peritoneale al Centro Médico Teknon in Spagna dal 2020 e presso il Dipartimento di Oncologia Peritoneale al Consorci Sanitari Integral dal 2010. In precedenza, il medico ha lavorato in chirurgia laparoscopica e robotica avanzata, nonché in chirurgia epatobiliare e pancreatica in vari ospedali prestigiosi in Spagna e Italia.<\/p>
Come esperto riconosciuto, il medico interviene frequentemente a congressi nazionali e internazionali sul trattamento chirurgico dei tumori addominali e pelvici avanzati e ha contribuito in modo significativo alla letteratura scientifica e agli studi clinici in chirurgia oncologica.<\/p>
Il medico è membro di diverse società chirurgiche e oncologiche stimate, tra cui GECOP, SEOQ, AEC, ESSO e PSOGI.<\/p>
Il medico possiede una laurea in Medicina presso l'Università Complutense di Madrid e un dottorato presso l'Università di Barcellona. Specializzandosi in Ematologia e Oncologia Pediatrica presso l'Università del Maryland, il medico è esperto nel trattamento di tumori ossei e cerebrali, nonché di leucemia e malattie ematologiche.<\/p>
Con oltre due decenni di esperienza, il medico attualmente dirige l'Unità di Ematologia e Oncologia Pediatrica presso l'Ospedale HM Montepríncipe, concentrandosi sulla cura di bambini e adolescenti. In precedenza, il medico ha ricoperto la stessa posizione presso l'Ospedale Universitario Clínica San Rafael ed è autore di numerose pubblicazioni scientifiche.<\/p>
Il dottore è un educatore e ricercatore affermato nel campo dell'oncologia, con un'ampia esperienza di insegnamento presso USP CEU. Il dottore ha insegnato una vasta gamma di materie, tra cui Patologia Medica Generale, Oncologia Orale e Maxillo-facciale e Bioetica. Come tutor per studenti di medicina e rotanti esterni, il dottore ha contribuito significativamente alla formazione dei futuri professionisti della salute.<\/p>
Inoltre, il dottore ricopre la posizione di Direttore della ricerca post-laurea in oncologia clinica e applicata presso HM CIOCC USP CEU ed è responsabile delle pratiche di master post-laurea. Il dottore ha anche completato corsi avanzati presso il MD Anderson Cancer Center.<\/p>
Spanish oncologists prioritize the Barcelona Clinic Liver Cancer (BCLC) system to evaluate stage 3 liver cancer. This framework integrates tumor volume with liver function and patient fitness. While surgeons also use the TNM system for anatomical staging, BCLC guides all primary treatment decisions.
Bookimed Expert Insight: Spanish oncology centers often provide specialized care through multi-departmental hubs. For example, Hospital Universitario HM Madrid manages 4 comprehensive oncology centers to process over 2.3 million outpatients annually. This high volume allows specialists to refine BCLC staging accuracy, which is critical because a stage B diagnosis may lead to regional chemoembolization, while stage C requires systemic immunotherapy.
Patient Consensus: Patients note that the term stage 3 is often used loosely during initial talks. They emphasize asking doctors specifically for the BCLC and Child-Pugh scores to understand why certain treatments, like surgery, may or may not be an option.
Surgery or liver transplantation is possible for specific stage 3 cases through downstaging or conversion protocols. Specialists evaluate tumor burden, liver function, and vascular involvement. Patients meeting downstaging criteria after localized therapy like chemoembolization may regain transplant eligibility at specialized Spanish oncology centers.
Bookimed Expert Insight: Spanish liver units show a pattern of surgical adaptability. Clinica Universidad de Navarra is recognized as a leader in organ transplants and complex oncology. Data indicates that high-volume centers like Centro Médico Teknon, performing over 23,000 operations annually, often accept advanced cases for multidisciplinary review. These institutions utilize tumor boards to identify candidates for resection who were previously deemed ineligible at smaller facilities.
Patient Consensus: Patients emphasize that staging labels can be misleading. Many report that seeking a second opinion at a high-volume liver center significantly changed their treatment plan and surgical options.
Spanish oncology centers routinely provide local-regional treatments like radioembolization (TARE), chemoembolization (TACE), and stereotactic radiation (SBRT) for stage 3 liver cancer. These therapies manage portal vein thrombosis and high intrahepatic tumor burden alongside systemic immunotherapy to improve survival.
Bookimed Expert Insight: Spanish liver cancer care is driven by the Barcelona Clinic Liver Cancer (BCLC) protocol. High-volume centers like Clinica Universidad de Navarra and Centro Médico Teknon allow for rapid multidisciplinary board reviews. Data shows these centers integrate interventional radiology and oncology teams to offer TARE where smaller hospitals might only provide standard chemotherapy. Accessing these specialized units directly can significantly expand your local treatment options.
Patient Consensus: Patients note that receiving treatment in large tertiary hospitals is vital because smaller clinics often lack the interventional radiology equipment for specialized procedures like TARE or SIRT. They emphasize asking clearly about chemoembolization versus surgical resection early in the process.
First-line systemic therapy in Spain for stage 3 liver cancer primarily utilizes atezolizumab paired with bevacizumab. This combination follows European Society for Medical Oncology (ESMO) guidelines. Specialized centers like Clinica Universidad de Navarra and Centro Médico Teknon provide these immuno-oncology protocols to target advanced tumor cells effectively.
Bookimed Expert Insight: Spain’s research-heavy approach means major centers often prioritize systemic combinations over traditional chemotherapy. Our data shows Clinica Universidad de Navarra was the first in Spain to earn JCI accreditation. It maintains specialized oncology units that integrate immunotherapy with advanced imaging. For stage 3 cases, Spanish oncologists frequently reassess patients for secondary resection after systemic therapy. This provides a clear advantage for patients seeking curative options rather than just management.
Patient Consensus: Patients note that eligibility for these modern drugs depends heavily on liver function and bleeding risk. Many were surprised to learn that immunotherapy, rather than traditional chemotherapy, has become the standard frontline approach across Spanish clinics.
Spanish hospitals like Clinica Universidad de Navarra and Centro Médico Teknon lead in specialized liver cancer care. These centers utilize the Barcelona Clinic Liver Cancer (BCLC) staging system to guide treatment. Facilities hold Joint Commission International (JCI) accreditation and provide advanced surgeries and radioembolization.
Bookimed Expert Insight: While major centers in Madrid and Barcelona are popular, Clinica Universidad de Navarra stands out for its long-standing Joint Commission International (JCI) status and ESMO accreditation. This combination is rare and signals a high focus on oncology research and patient safety. For stage 3 cases, this dual credentialing often means better access to multidisciplinary tumor boards and emerging systemic therapies.
Patient Consensus: Patients emphasize finding large university centers with high-volume hepatobiliary teams for complex cases. They often recommend seeking a second opinion at these major facilities before starting treatment to ensure every surgical or transplant option is explored.